James A. Beer: Well, as you say, the guidance that we have there in the press release talks about growth in FY 2015. It’s between the high-single-digit realm. Yes, that is lower than the percentage growth that we saw for generics that are past that exclusivity period that we saw in fiscal 2014. So, it is a relative headwind year-over-year, but still growth for fiscal 2015 year-over-year.
James A. Beer: Well, we stand by the $1 to $1.20 of accretion for 100% of the ownership. Of course, as you say, we’re only at 76% and that was for the first 12 months of operations, after beginning of February. So in essence, we got the first two months of that in the Q4, just finished and then the balance of the 10 months, we’d be receiving in fiscal 2015. Now, the reason that we ended up net neutral in fiscal 2014 was because we had this one-time inventory write-up consistent with the acquisition accounting and so forth.Glen J. Santangelo – Credit Suisse Securities LLC: Okay, okay. Thank you.
James A. Beer: Yes. We would expect interest expense to be rising year-over-year, consistent with the new debt that we took on to finance Celesio. So that is all publicly available and so I’ll just leave at there at the moment.Charles Rhyee – Cowen & Co. LLC: Great, thank you.
James A. Beer: Yes. It added about $8 billion in revenue in fiscal fourth quarter.Greg T. Bolan – Sterne, Agee & Leach, Inc.:  Okay, got it.
James A. Beer: Well, just one thing I misspoke on the Celesio revenue that was $4.8 billion in Q4, not $8 billion.Greg T. Bolan – Sterne, Agee & Leach, Inc.: Got it, thank you.
James A. Beer: So in terms of the mix of earnings during the year, what I would point to is that last year, we had particularly strong earnings in the first half of the year, year-over-year and that was driven by somewhat unusually high generic price increase activity. So returning in our fiscal 2015 plan to more the profile that we saw in fiscal 2013 back through fiscal 2011 that type of picture in some quarterly seasonality.Greg T. Bolan – Sterne, Agee & Leach, Inc.: Okay, that’s very helpful. Thank you.
James A. Beer: By far the most significant driver there are the purchasing synergies that we would look to be able to attain over time. As John said, we’d look to get to $275 million to $325 million per year by year four. So, it will really be that procurement synergy effort that drives that to some modest amount of tank savings that we believe will be available as well.David M. Larsen – Leerink Partners LLC:  Great. Thanks a lot.
John H. Hammergren: Steven, these are price trends, not the growth of the market overall. This is just the trend of price inflation on generics. So we do expect this year to be a good launch year for generics.Steven J. Valiquette – UBS Securities LLC:  Okay. For the quarter just reported though, was there pretty consistent trends in the March quarter versus what you saw back in the December quarter sequentially or was there a little bit of tapering off on some of the economics tied to that? Just curious on the sequential quarterly trend.
John H. Hammergren: Well, at the beginning of the year, we talked about the strength in the first half of the year and we expected that to moderate in the back half and that’s exactly what we saw in our third and fourth quarters.Steven J. Valiquette – UBS Securities LLC: Okay, perfect. Thanks.
John H. Hammergren: That’s correct. We have to go through a couple of more steps. We don’t believe there is any risk in us not obtaining operational control, but we don’t have it automatically just from ownership. We don’t need 100% to get operational control. So what will happen is, we’ll get this operational control, which will allow us to be more interactive with the company than we can today, because we still have a responsibility with regard to operational control to manage the business independent of McKesson and that will change when we achieve operational control. The difference between 76% and 100% ownership is just how much of the earnings we actually consolidated in the end and that’s what James was trying to describe. So we have 100% of the revenue in, we take out the minority ownership from an earnings perspective on that full schedule.Lisa C. Gill – JPMorgan Securities LLC: Okay, that’s very helpful.
John H. Hammergren: Well, it’s difficult for us to talk about their view of their markets until we get operational controls. So I think you should expect us to be more open and perhaps, discuss more freely what’s going on in the various businesses inside of Celesio and various markets inside of Celesio. Our view, I have spent a lot of time in Europe now with the country managers and I think Paul, and I both would share a point of view that business is run by professional managers we respect and admire what they are doing in many of their markets. And in their press release this morning, they did talk about the strength in their European pharmacy network activities and the strength in particular, Lloyds out of the U.K. and we certainly have seen some of that in our travels. I think it’s probably difficult for us to speculate at this point what will happen with the German discounting in the outside our end of our fiscal year, which is really what they are referring to.Lisa C. Gill – JPMorgan Securities LLC: Okay, great. Thank you for the clarification.
John H. Hammergren: I think it will ramp up over the next half of the year. Next two to three months, we should be well into it.Ricky Goldwasser – Morgan Stanley & Co. LLC: Thank you.
John H. Hammergren: When I spoke about the Rite Aid implementation, the first step really was to bring the combined volumes of our corporations together and go to the marketplace to make sure that we are providing the best opportunity to the manufacturers to gain access to that share position. We are now in the process of implementing the generics actually into – the distribution business into Rite Aid, but the value for McKesson relative to the renegotiation should begin to be realized basically effective right now at the beginning of this fiscal year. I might note however that none of the Celesio synergies or volumes or generic purchases, et cetera have been included in any of this upfront work with the manufacturers. It’s simply been McKesson’s business that has continued to grow and thrive, including the incremental Health Mart stores we’ve added, as well as the increment of Rite Aid generic bind that we were able to put together and complete – as I said, substantially complete the negotiations with manufacturers as we sit here today. And clearly, as we get into the late summer months, we should be reworking those relationships to include the Celesio volume as well.Glen J. Santangelo – Credit Suisse Securities LLC:  So James, and if I could just follow up on that Celesio accretion analysis. Essentially, when you guys first announced the deal, I think you suggested it’d be a $1 to $1.20 accretive and that was with very modest synergies. Now that you have76% ownership, should we think about that year one accretion being in the $0.75 to $0.80 range with only moderate synergies because based on John’s comments, it kind of sounds like the Company hasn’t been able to bring those volumes into the fold and start to really exercise some of that synergy potential at this point.
John H. Hammergren: We continue to make great progress with NorthStar and in fact, have launched a version of NorthStar that’s called, Savant in Canada. And so both of those product lines are continuing to gain momentum. Now, clearly, we’re working closely with the manufacturing community to make sure we’ve got the best choice of product and the best choice of partners and the Rite Aid agreement does include NorthStar as one of the value offerings to both companies. As it relates to Celesio, which is probably premature to talk about, what we might be able to do with NorthStar or with the NorthStar model as it relates to many of the markets in Europe, but we clearly will have that as part of our evaluation as we get into that next phase.George R. Hill – Deutsche Bank Securities, Inc.:  Maybe a quick follow-up. A couple of your competitors are using JV or GPO type structures for the procurement of generic drugs. Is that something that makes sense to do with the inclusion of Celesio, or is the straight integration just McKesson buying the drugs directly from manufacturers and selling through the – I guess, through the supply chain, is that the right way? I guess, I’m just trying to think about industry structure going forward? Thank you.
John H. Hammergren: No problem, George. We don’t plan to have any JVs or any type of unusual structure to get access to the synergy we believe are possible, and there was no JV structure as it relates to Rite Aid, will not be one related to Celesio. It will be McKesson’s sourcing operation that does all of the work.George R. Hill – Deutsche Bank Securities, Inc.: Thank you.
John H. Hammergren: Well, it’s a little bit of both. A part of that coordination activity is to make sure we’re getting after the synergies that we think exist in the primary synergies we’ve outlined in our conversations regarding Celesio is around product sourcing. so clearly, that’s a top priority and those teams are already beginning to do some work. But as I said it really can’t accelerate until we get pass this operational control phase. With the other part of the project management or coordination office role is to make sure that we understand what Celesio is working on today and what they might need our assistance with, things like IT or other kinds of projects that we might be able to lend a helping hand to. So, I would say that it’s basically a process of understanding more completely Celesio’s operations and corporate functions, so that work is under way.Charles Rhyee – Cowen & Co. LLC:  Great. And as a follow-up James. I don’t know if I saw it in the assumptions you gave on the guidance. Can you give us an estimate of, what sort of interest expense are you expecting for fiscal 2015? Thank you.
John H. Hammergren: We do see that pressure. It ebbs and flows depending on the markets and where our physicians are based. I would say that the pressure is not coming from payers and it’s not coming from patients. The pressure is usually driven by the purchase of a practice where a local hospital or hospital system decides to buy a group of oncologists that were customers of McKesson. And many times if the hospital is a customer of McKesson, we’ll retain all of that business, clearly if it just go through standard distribution. But I think the beauty of the U.S. Oncology model is that, many times we’re able to follow those physicians into the hospital setting and begin to manage the practices on behalf of the hospital, maybe you pick up net new physicians that are part of the network as the hospital relies on our expertise to continue to work with those doctors to optimize the quality of care and the cost of that care. So, although it continues to be something we have to pay attention to, and on occasion we’ll lose a practice if a customer that goes into a hospital and we don’t have any affiliation with the hospital afterwards and obviously, that’s a net loss for us. But I would say the team has been very good at working with our customers in these transitions and retaining our position.Robert P. Jones – Goldman Sachs & Co.: Got it. Thanks. 
John H. Hammergren: So that’s an accretion number, not a synergy number. The synergy number was $275 million to $325 million realized over four years, with a modest impact this fiscal year.
John H. Hammergren: So operator, I don’t think there are any other questions on the phone. So, I think that we’ll wrap this up. I want to thank all of you on the call today for your time. We certainly have a strong plan in place for fiscal 2015 and we’re excited about the tremendous growth opportunities that are available to us across McKesson. I’m certainly once again; proud of our track record in our delivery to our customers and the tremendous financial returns we’ve delivered to our shareholders this year and for many years, and I also want to thank all of our tremendous employees for their effort this last year on driving that success for us. With that, I’ll turn it over to Erin for a view of upcoming events for the financial community.
